NRXS Neuraxis
- 2.990
- -0.010-0.33%
Neuraxis News
Express News | Neuraxis Inc: New Submission to FDA to Expand Label for Ib-Stim Which Would Include Ages 8-21, and 4 Devices Over 4 Weeks
Express News | Neuraxis Announces New Submission to the FDA for the Expansion of Its Ib-Stim Label; Provides Compliance With NYSE Guidelines on Audit Disclosure
Earnings Call Summary | Neuraxis(NRXS.US) Q1 2024 Earnings Conference
The following is a summary of the NeurAxis, Inc. (NRXS) Q1 2024 Earnings Call Transcript:Financial Performance:NeurAxis generated a Q1 revenue of $646,000 from 222 patient treatments, showing high dem
Neuraxis Q1 2024 GAAP EPS $(0.32) Up From $(1.18) YoY, Sales $646.635K Miss $2.229M Estimate
Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.32) per share. This is a 72.88 percent increase over losses of $(1.18) per share from the same period last year. The company reported quarterly s
Earnings Flash (NRXS) NEURAXIS Posts Q1 Revenue $646,635
08:02 AM EDT, 05/22/2024 (MT Newswires) -- Earnings Flash (NRXS) NEURAXIS Posts Q1 Revenue $646,635
Neuraxis 1Q Sales $646,635 >NRXS
Neuraxis 1Q Sales $646,635 >NRXS
Express News | Neuraxis Reports First Quarter 2024 Financial Results
NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
Neuraxis | 10-Q: Quarterly report
NeurAxis Announces Publication Of Medical Policy Coverage For Percutaneous Electrical Nerve Field Stimulation With A Blue Cross Blue Shield License In FL
NeurAxis Announces Publication Of Medical Policy Coverage For Percutaneous Electrical Nerve Field Stimulation With A Blue Cross Blue Shield License In FL
NeurAxis Announces New Medical Policy Coverage For Nearly Six Million Lives in Florida
NeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024
CARMEL, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating
NeurAxis Announces New Medical Policy Coverage in North Dakota
CARMEL, Ind., April 23, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressin
Neuraxis (NRXS.US): The 2023 Q4 financial report achieved revenue of US$531.46 million, with an expected value of US$1.61 million; earnings per share of -0.85 US dollars.
Neuraxis (NRXS.US): The 2023 Q4 financial report achieved revenue of US$531.46 million, with an expected value of US$1.61 million; earnings per share of -0.85 US dollars.
NeurAxis, Inc. (NASDAQ:NRXS) Q4 2023 Earnings Call Transcript
NeurAxis Reports Q4 Results
Earnings Call Summary | Neuraxis(NRXS.US) Q4 2023 Earnings Conference
The following is a summary of the NeurAxis, Inc. (NRXS) Q4 2023 Earnings Call Transcript:Financial Performance:NeurAxis experienced a decrease in revenues in fiscal year 2023 to $2.5 million, down 8.4
NeurAxis, Inc. (NRXS) Q4 2023 Earnings Call Transcript
NeurAxis, Inc. (NRXS) Q4 2023 Earnings Call Transcript
Press Release: NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results CARMEL, Ind., April 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical
Earnings Scheduled For April 9, 2024
Companies Reporting Before The Bell • Tilray Brands (NASDAQ:TLRY) is projected to report quarterly loss at $0.05 per share on revenue of $198.62 million. • Cognyte Software (NASDAQ:CGNT) is likely to
Analysis
Price Target
No Data
